NEWRON PHARMACEUT. EO-20 (NP5) - Total Assets

Latest as of December 2025: €40.03 Million EUR ≈ $46.80 Million USD

Based on the latest financial reports, NEWRON PHARMACEUT. EO-20 (NP5) holds total assets worth €40.03 Million EUR (≈ $46.80 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check NP5 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.

NEWRON PHARMACEUT. EO-20 - Total Assets Trend (2005–2025)

This chart illustrates how NEWRON PHARMACEUT. EO-20's total assets have evolved over time, based on quarterly financial data. Check NP5 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.

NEWRON PHARMACEUT. EO-20 - Asset Composition Analysis

Current Asset Composition (December 2025)

NEWRON PHARMACEUT. EO-20's total assets of €40.03 Million consist of 95.1% current assets and 4.9% non-current assets.

Asset Category	Amount (EUR)	% of Total Assets
Cash & Equivalents	€0.00	30.4%
Accounts Receivable	€6.16 Million	15.4%
Inventory	€0.00	0.0%
Property, Plant & Equipment	€0.00	0.0%
Intangible Assets	€999.29	0.0%
Goodwill	€0.00	0.0%

Asset Composition Trend (2005–2025)

This chart illustrates how NEWRON PHARMACEUT. EO-20's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NEWRON PHARMACEUT. EO-20 (NP5) market capitalisation.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: NEWRON PHARMACEUT. EO-20's current assets represent 95.1% of total assets in 2025, an increase from 90.6% in 2005.
Cash Position: Cash and equivalents constituted 30.4% of total assets in 2025, down from 74.3% in 2005.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
Asset Diversification: The largest asset category is accounts receivable at 15.4% of total assets.

NEWRON PHARMACEUT. EO-20 Competitors by Total Assets

Key competitors of NEWRON PHARMACEUT. EO-20 based on total assets are shown below.

Company	Country	Total Assets
Biomarin Pharmaceutical Inc NASDAQ:BMRN	USA	$8.59 Billion
Cyclacel Pharmaceuticals Inc NASDAQ:CYCC	USA	$4.40K
Krystal Biotech Inc NASDAQ:KRYS	USA	$1.40 Billion
Verona Pharma PLC ADR NASDAQ:VRNA	USA	$572.87 Million
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	USA	$641.76 Million
Beijing Tiantan Biological Products Corp Ltd SHG:600161	China	CN¥16.55 Billion
Hebei Changshan Biochem Pharma SHE:300255	China	CN¥4.66 Billion
BB Biotech AG SW:BION	Switzerland	CHF2.64 Billion

NEWRON PHARMACEUT. EO-20 - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	0.76	2.60	5.50
Quick Ratio	0.76	2.60	5.37
Cash Ratio	0.00	0.00	0.00
Working Capital	€-12.04 Million	€37.60 Million	€30.98 Million

NEWRON PHARMACEUT. EO-20 - Advanced Valuation Insights

This section examines the relationship between NEWRON PHARMACEUT. EO-20's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	199.36
Latest Market Cap to Assets Ratio	7.67
Asset Growth Rate (YoY)	-37.4%
Total Assets	€40.03 Million
Market Capitalization	$306.87 Million USD

Valuation Analysis

Premium Asset Valuation: The market values NEWRON PHARMACEUT. EO-20's assets at a significant premium (7.67x), suggesting investors see substantial growth potential or unique competitive advantages.

Significant Asset Reduction: NEWRON PHARMACEUT. EO-20's assets decreased by 37.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for NEWRON PHARMACEUT. EO-20 (2005–2025)

The table below shows the annual total assets of NEWRON PHARMACEUT. EO-20 from 2005 to 2025.

Year	Total Assets	Change
2025-12-31	€40.03 Million ≈ $46.80 Million	-37.37%
2024-12-31	€63.91 Million ≈ $74.72 Million	+147.07%
2023-12-31	€25.87 Million ≈ $30.24 Million	-30.46%
2022-12-31	€37.20 Million ≈ $43.48 Million	-26.33%
2021-12-31	€50.49 Million ≈ $59.02 Million	-1.39%
2020-12-31	€51.20 Million ≈ $59.86 Million	-15.08%
2019-12-31	€60.29 Million ≈ $70.48 Million	+0.48%
2018-12-31	€60.00 Million ≈ $70.15 Million	-17.84%
2017-12-31	€73.02 Million ≈ $85.37 Million	+29.04%
2016-12-31	€56.59 Million ≈ $66.16 Million	+27.51%
2015-12-31	€44.38 Million ≈ $51.88 Million	+19.71%
2014-12-31	€37.07 Million ≈ $43.34 Million	+17.26%
2013-12-31	€31.62 Million ≈ $36.96 Million	-29.18%
2012-12-31	€44.65 Million ≈ $52.20 Million	+229.11%
2011-12-31	€13.57 Million ≈ $15.86 Million	-29.09%
2010-12-31	€19.13 Million ≈ $22.37 Million	-54.10%
2009-12-31	€41.68 Million ≈ $48.73 Million	-31.16%
2008-12-31	€60.54 Million ≈ $70.78 Million	-13.97%
2007-12-31	€70.37 Million ≈ $82.27 Million	-18.33%
2006-12-31	€86.16 Million ≈ $100.73 Million	+266.67%
2005-12-31	€23.50 Million ≈ $27.47 Million	--

About NEWRON PHARMACEUT. EO-20

XETRA:NP5 Germany Biotechnology

Market Cap

$306.87 Million

€262.49 Million EUR

Market Cap Rank

#14813 Global

#1466 in Germany

Share Price

€13.15

Change (1 day)

+0.77%

52-Week Range

€7.16 - €32.55

All Time High

€32.55